Galectin Therapeutics (GALT) Reports Q2 Loss of $0.14/Share

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.14), versus ($0.20) reported last year.

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Waste stocks ride AI and healthcare boom as CLH surges 27%
• Bending Spoons closes IPO, raises ~$954M on Nasdaq